Compare ADMA Biologics Inc (ADMA) vs Coursera Inc (COUR) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Coursera (COUR) trades at $5.80, down 1.69% today, with a bullish technical signal from moving averages. Revenue grew to $757.5M in 2025, though net income remains negative at -$51M. The company completed its merger with Udemy in May 2026, aiming for synergies, and announced a $500M share repurchase program. Positive cash flow from operations of $108.7M supports financial stability.

The outlook is mixed: analyst consensus targets $8.00 (37.9% upside), with 53% buy ratings, but persistent losses and competitive pressures pose risks. Earnings misses in recent quarters highlight execution challenges. The stock offers growth potential via market expansion and merger benefits, yet profitability concerns and market volatility require cautious evaluation.